Replies to post #1552 on EDAP TMS S.A. (EDAP)

[Batermere]

FYI: EDAP received the LONG AWAITED FDA approval for Ablatherm HIFU for prostate cancer almost a year ago, November 9th, 2015. That was supposed to propel EDAP up into the stratosphere here in America. Since then, the stock price has plummeted. It didn't do anything positive for EDAP long term because the boys running this company in Lyons, France, have NO IDEA how to market and sell the device here. The sad thing is that it actually works very well. What would be different with FDA approval of Focal One? Not a thing. The dilution that occurred at $3.50 was to be used to properly train EDAP salespeople/technicians on how to sell and then educate the urologists on how to use it properly here in the USA. That obviously hasn't happened. They haven't a clue how to manage/operate their company in the USA. Call it the "French Way".... lazy, unmotivated and pathetically incompetent.